Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

19310 items
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

GOP voice for price oversight

WASHINGTON - Maine Sen. William Cohen, the ranking minority member of the Senate Special Committee on Aging who joined Democratic chairman Sen. David Pryor last week to express reservations about the pricing of Betaseron, may...
12:00 AM, Aug 16, 1993  |  BioCentury | Finance

Dampening expectations

Noteworthy Dampening expectations Regeneron Pharmaceuticals Inc. stock responded negatively to the company's disclosure last week that there was no significant difference between drug and placebo in its Phase II trial of ciliary neurotrophic factor to...
12:00 AM, Aug 16, 1993  |  BioCentury | Strategy

DNX finds allure in service business

Noteworthy DNX finds allure in service business If DNX Corp. (DNXX) doesn't find a partner for its core blood substitute program, it may transform itself into a different company focused on its preclinical services division,...
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

The Pryor-Cohen letter

The Pryor-Cohen letter The lawmakers appended four questions arising from prior contacts with the company, which Berlex said it intends to answer this week. The questions are not included here because the context is not...
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

White House handbook for selling health plan

White House handbook for selling health plan WASHINGTON - A briefing book on the Clinton administration's planned health care reforms, which the White House distributed to Democratic members of Congress last week, contains strongly worded...
12:00 AM, Aug 16, 1993  |  BioCentury | Politics, Policy & Law

A real pot-boiler

A real pot-boiler A CEO once told us that his job was to turn the heat up under the pot of water, and keep turning it up until the water roiled up and splattered over...
12:00 AM, Aug 16, 1993  |  BioCentury | Product Development

CTII's cell therapy for diabetes

Noteworthy CTII's cell therapy for diabetes CytoTherapeutics Inc. was to announce today that it has begun Phase I trials of polymer-encapsulated islet cells that will be implanted in patients with Type I insulin-dependent diabetes and...
12:00 AM, Aug 09, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Medarex Inc. (MEDX) Michael Feeley of Feeley & Willcox reaffirmed his "buy" recommendation. Feeley said MEDX's Bispecific antibody technology has broad patent coverage and potentially could address a wide variety of markets. He said MEDX...
12:00 AM, Aug 09, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Vical Inc. (VICL) Reijer Lenstra of SoundView Financial Group initiated coverage with a "buy" rating. Lenstra said VICL's technology for the direct insertion of naked DNA into muscle is simple, safe, inexpensive and efficacious and...
12:00 AM, Aug 09, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Teva Pharmaceutical Industries (TEVIY) Treppel also began coverage with a "strong buy." In addition to branded ethical pharmaceuticals and generics, TEVIY has developed one proprietary drug, Alpha-D3 for renal failure. Treppel said TEVIY is well...

Pages